Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OR6O
|
|||
| Former ID |
DIB019155
|
|||
| Drug Name |
CM-352
|
|||
| Synonyms |
compound 2 [PMID 25686022]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C24H29N3O6S
|
|||
| Canonical SMILES |
CNC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)C3(CCC4(C3)CCNCC4)C(=O)NO
|
|||
| InChI |
1S/C24H29N3O6S/c1-25-21(28)17-2-4-18(5-3-17)33-19-6-8-20(9-7-19)34(31,32)24(22(29)27-30)11-10-23(16-24)12-14-26-15-13-23/h2-9,26,30H,10-16H2,1H3,(H,25,28)(H,27,29)/t24-/m1/s1
|
|||
| InChIKey |
ZUZGJCNWNOCKEB-XMMPIXPASA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-10 (MMP-10) | Target Info | Inhibitor | [2] |
| Matrix metalloproteinase-3 (MMP-3) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | TNF signaling pathway | |||
| Transcriptional misregulation in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Panther Pathway | Plasminogen activating cascade | |||
| CCKR signaling map ST | ||||
| Pathway Interaction Database | Posttranslational regulation of adherens junction stability and dissassembly | |||
| p75(NTR)-mediated signaling | ||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| EGFR Transactivation by Gastrin | ||||
| WikiPathways | Activation of Matrix Metalloproteinases | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Oncostatin M Signaling Pathway | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke. J Thromb Haemost. 2013 Aug;11(8):1464-73. | |||
| REF 2 | Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015 Apr 9;58(7):2941-57. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.